Philips launches NightBalance, increasing therapy options for positional obstructive sleep apnea patients
September 17 2019 - 8:00AM
September 17, 2019
- Clinically-validated sleep position treatment provides a
comfortable, easy-to-use alternative for positional obstructive
sleep apnea patients
- Updates include wireless connectivity and new mobile app
Amsterdam, the Netherlands – Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, today
announced the commercial launch of Philips NightBalance, a
prescription sleep position therapy device designed for patients
with positional obstructive sleep apnea (OSA). A mask-free
alternative to existing positional OSA treatments, Philips
NightBalance is a clinically-validated positional therapy that uses
gentle vibrations to encourage users to alter their sleeping
positions to help prevent apneas.
The new Philips NightBalance positional OSA technology features
wireless connectivity and a mobile app that monitors product use
and provides patients and physicians with access to data via a
cloud-based system.
More comfortable and easier to useMultiple
clinical studies have found that Philips NightBalance offers an
effective form of non-invasive treatment for positional OSA
patients. Most recently, a study funded by Philips in the Journal
of Clinical Sleep Medicine, “The POSAtive Study: Study for the
Treatment of Positional Obstructive Sleep Apnea,” found
NightBalance to be a non-inferior treatment to continuous positive
airway pressure (CPAP) and demonstrate high adherence rates among
positional OSA patients. In the study, data showed that patients
with positional OSA felt NightBalance was easier to use, easier to
adjust to and more comfortable than other PAP therapy methods.
Additionally, patients who used the sleep position treatment used
the device for greater lengths of time compared to PAP therapy,
with 74 percent of patients reported using NightBalance for more
than four hours, compared to 64.9 percent.
“We are always looking to evolve our solutions to help people
living with sleep apnea take control of their health,” said Mark
D’Angelo, Sleep OSA Business Leader at Philips. “The right sleep
therapy varies person-to-person, and for those who suffer from
positional obstructive sleep apnea, it can be defeating when
traditional therapies don’t meet their specific needs. With Philips
NightBalance, positional obstructive sleep apnea patients now have
a non-invasive and comfortable treatment option that can be
successful, resulting in long term therapy adherence.”
Today, over 100 million people worldwide suffer from obstructive
sleep apnea [1]. From that population, it is estimated that between
36 and 47 percent of these patients suffer from positional OSA, a
form of sleep apnea where breathing disturbances are present when
sleeping on the back [2]. Without treatment, positional OSA can
cause poor sleep and fatigue, ultimately impacting a patient’s
quality of life. Positional sleep apnea therapy, like Philips
NightBalance, is an effective form of non-invasive treatment for
those living with positional OSA for whom additional therapy
methods have been previously unsuccessful.
Leveraging nearly 40 years of deep clinical expertise in sleep
technology, Philips’ growing Sleep and Respiratory care portfolio
offers a broad range of solutions addressing both consumer and
clinical needs for patients with sleep disorders, or those who
simply need better sleep.
Philips NightBalance will be available through a prescription in
the United States, United Kingdom, Austria, Germany, Switzerland,
Belgium, the Netherlands and Luxembourg. For additional
information on Philips’ solutions for sleep and respiratory care,
follow @PhilipsResp on Twitter or visit
www.Philips.com/POSA-news.
[1] The Official STOP-BANG Questionnaire. Retrieved
from http://www.stopbang.ca/osa/prevalence.php. [2]
Heinzer, R. et al, Prevalence and Characteristics of
Positional Sleep Apnea in the HypnoLaus Population-based cohort,
Sleep Medicine 2018; 48:157-162
For further information, please contact:
Kathy O'Reilly Philips Global Press OfficeMobile: +1
978-221-8919E-mail : Kathy.OReilly@philips.com
Meredith Amoroso Philips Sleep and Respiratory Care Mobile: +1
724-584-8991 E-mail: Meredith.Amoroso@philips.com
About Royal PhilipsRoyal Philips (NYSE: PHG,
AEX: PHIA) is a leading health technology company focused on
improving people's health and enabling better outcomes across the
health continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. Headquartered in the Netherlands, the company is a
leader in diagnostic imaging, image-guided therapy, patient
monitoring and health informatics, as well as in consumer health
and home care. Philips generated 2018 sales of EUR 18.1 billion and
employs approximately 78,000 employees with sales and services in
more than 100 countries. News about Philips can be found
at www.philips.com/newscenter.
- Philips NightBalance for positional obstructive sleep apnea
patients
- Philips NightBalance
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Koninklijke Philips NV (NYSE:PHG)
Historical Stock Chart
From Sep 2023 to Sep 2024